Abstract: Various human monoclonal antibodies that bind to human LOX-1 and inhibit the binding of in-vivo LOX-1 ligands to LOX-1, and the LOX-1-mediated incorporation of the ligands into cells, were obtained by immunizing human antibody-producing transgenic mice (created by genetic engineering) with soluble human oxidized LDL receptor (LOX-1). Furthermore, the human monoclonal antibodies were found to be effective in preventing and treating a variety of diseases.

Abstract: A main object of the present invention is to provide a manufacturing method of a pattern formed body which makes it possible to form property varied patterns having a desired line width, even when plural pattern formed bodies are manufactured. To achieve the object, the invention provides a manufacturing method of pattern formed bodies, comprising: a pattern-forming step of radiating vacuum-ultraviolet light onto a patterning substrate, a surface property of which is varied by the vacuum-ultraviolet light, through a photomask having at least a transparent substrate and a light shielding part to form a pattern formed body having a property varied pattern, in which the surface property of the patterning substrate is varied; and a step of repeating the pattern-forming step to manufacture a plurality of the pattern formed bodies, wherein an interval between the transparent substrate and the patterning substrate upon the pattern-forming step is set into the range of 0.1 ?m to 200 ?m.

Abstract: Various human monoclonal antibodies that bind to human TGF-? type II receptor to inhibit the signal transduction of human TGF-? signal into cells are produced by immunizing human antibody-producing transgenic mice generated by genetic engineering techniques with the soluble human TGF-? type II receptor. Further, these human monoclonal antibodies were demonstrated to be effective for preventing and treating various diseases induced by human TGF-? in various organs (for example, tissue fibrosis).

Abstract: Various human monoclonal antibodies that bind to human LOX-1 and inhibit the binding of in-vivo LOX-1 ligands to LOX-1, and the LOX-1-mediated incorporation of the ligands into cells, were obtained by immunizing human antibody-producing transgenic mice (created by genetic engineering) with soluble human oxidized LDL receptor (LOX-1).

Abstract: A main object of the present invention is to provide a production method for a color filter capable of producing a color filter with little white spots by the ink jet method, without limitation of the application derived from the presence of the moisture. To achieve the object, the invention provides a production method for a color filter using a substrate for a color filter having a base material, and a light shielding part formed on the base material and having a plurality of opening parts, comprising: a lyophilic process step of processing each of a base material surface in the opening parts to be lyophilic by contacting each of the base material surface in the opening parts with lyophilic process solution which contains an organic solvent having a hydroxyl group and no water; and a colored layer forming step of forming a colored layer on each of the base material surface in the opening parts processed to be lyophilic in the lyophilic process step by an ink jet method.

Abstract: A main object of the present invention is to provide a production method for a color filter capable of producing a color filter with little white spots by the ink jet method. To achieve the object, the present invention provides a production method for a color filter using a substrate for a color filter comprising a base material, and a light shielding part formed on the base material and having a plurality of opening parts, comprising: a lyophilic process step of processing each of a base material surface in the opening parts to be lyophilic by contacting each of the base material surface in the opening parts with lyophilic process solution containing a water soluble organic solvent having a hydroxyl group and water, and a colored layer forming step of forming a colored layer on each of the base material surface in the opening parts processed to be lyophilic in the lyophilic process step by an ink jet method.

Abstract: A main object of the present invention is to provide a manufacturing method of a pattern formed body which makes it possible to form property varied patterns having a desired line width, even when plural pattern formed bodies are manufactured. To achieve the object, the invention provides a manufacturing method of pattern formed bodies, comprising: a pattern-forming step of radiating vacuum-ultraviolet light onto a patterning substrate, a surface property of which is varied by the vacuum-ultraviolet light, through a photomask having at least a transparent substrate and a light shielding part to form a pattern formed body having a property varied pattern, in which the surface property of the patterning substrate is varied; and a step of repeating the pattern-forming step to manufacture a plurality of the pattern formed bodies, wherein an interval between the transparent substrate and the patterning substrate upon the pattern-forming step is set into the range of 0.1 ?m to 200 ?m.

Abstract: Various human monoclonal antibodies that bind to human LOX-1 and inhibit the binding of in-vivo LOX-1 ligands to LOX-1, and the LOX-1-mediated incorporation of the ligands into cells, were obtained by immunizing human antibody-producing transgenic mice (created by genetic engineering) with soluble human oxidized LDL receptor (LOX-1). Furthermore, the human monoclonal antibodies were found to be effective in preventing and treating a variety of diseases.

Abstract: Monoclonal antibodies which have binding specificity to human CETP(CETP inhibition activity) and which are useful as reagents for purification or quantification of human CETP, and as pharmaceuticals to prevent and/or treat hyperlipidemia or arteriosclerosis are provided. Furthermore, purification and quantification methods of human CETP by using the monoclonal antibodies are also provided.

Abstract: Monoclonal antibodies which have binding specificity to human CETP (CETP inhibition activity) and which are useful as reagents for purification or quantification of human CETP, and as pharmaceuticals to prevent and/or treat hyperlipidemia or arteriosclerosis are provided. Furthermore, purification and quantification methods of human CETP by using the monoclonal antibodies are also provided.